Core Insights - The report highlights the ongoing geopolitical conflicts and their impact on capital markets, particularly the volatility in the A-share market and the upcoming earnings disclosure period [2][5] - It discusses the potential outcomes of the Iran conflict, suggesting that military results may emerge in April, which could affect market risk preferences [2][5] - The report anticipates strong performance in sectors with high economic momentum, including non-bank financials, chemicals, and telecommunications, while also identifying recovery sectors such as home appliances and retail [6] Industry Overview - The report categorizes industries based on their economic momentum, identifying expansionary sectors like non-bank financials, chemicals, and telecommunications, and recovery sectors including home appliances, food and beverage, and retail [6] - It notes that the chemical sector benefits from rising upstream energy prices, while the coal sector is seeing improved supply-demand dynamics [6] - The consumer chain is expected to recover gradually, with food and beverage production showing year-on-year growth, and home appliances benefiting from overseas inventory replenishment [6] Investment Strategy - The report recommends a "HALO PLUS" strategy, focusing on defensive investments in high cash flow and low correlation sectors, such as coal and utilities, while also targeting growth sectors with low competition and sensitivity to interest rates [6] - It emphasizes the importance of maintaining a balanced portfolio to hedge against macroeconomic volatility [6] Stock Recommendations - The report lists ten recommended stocks, including TCL Electronics, Anjuke Food, Muyuan Foods, and Tencent Holdings, highlighting their growth potential and market positioning [3][4]

Group 1 - The stock price of Chengda Pharmaceutical (301201) experienced significant fluctuations, with a single-day increase of 3.17% on February 12, 2026, and a total market capitalization of 6.351 billion yuan [1] - The market focus is on sectors such as cell immunotherapy, hepatitis concepts, and CRO concepts, which are driving investor interest [1] - On February 13, the stock continued its upward trend, closing at 41.67 yuan, reflecting a 1.51% increase from the previous day [1] Group 2 - Over the past 7 trading days (February 6 to February 13, 2026), the stock price rose from 38.05 yuan to 41.67 yuan, marking a cumulative increase of 9.51% with a volatility of 11.30% [2] - On February 12, there was a net inflow of 17.2629 million yuan from main funds, indicating a continuous increase in positions for two consecutive days [2] - As of February 11, the balance of margin financing and securities lending was 305 million yuan, showing a decrease of 0.42% from the previous day [2]

Core Insights - The report emphasizes the historical positioning of silver indicators, noting that 93% of historical dates are below 200%, while the current level exceeds 1800%, indicating potential price adjustments during the decline phase of silver [11] - It highlights the macroeconomic narratives, including geopolitical tensions and the impact of the new Federal Reserve chair, suggesting that the current market is less influenced by overseas factors [3][12] - The investment strategy focuses on three main areas: core growth assets, global competitive advantages, and emerging growth sectors, with specific recommendations for companies in these categories [14] Company Summaries TCL Electronics (01070) - TCL Electronics is forming a joint venture with Sony, where TCL will hold 51% and Sony 49%, aiming to leverage cost and technology advantages in the large-size and mini LED sectors [15] - The joint venture is expected to enhance TCL's high-end product series capabilities [15] Mao Geping (01318) - The brand is expanding its global presence with a new store in Hong Kong and a focus on integrating Eastern aesthetics with modern art, enhancing its international brand narrative [16] Anjuke Food (603345) - The company is shifting from a reliance on large B2B clients to a selective supermarket customization strategy, collaborating with major retailers to launch tailored products, resulting in a 28.1% year-on-year revenue increase in the supermarket channel [17] Chengda Pharmaceutical (301201) - Chengda is transitioning towards biocell therapy, developing innovative drug pipelines and forming strategic partnerships, including a significant collaboration with Chiron Pharma, which has led to clinical advancements [19] Xinquan Co., Ltd. (603179) - The company has established strong partnerships with major domestic truck manufacturers and is focused on expanding its automotive component offerings, leveraging over 20 years of industry experience [20] Jianghuai Automobile (600418) - Jianghuai is developing a new generation of high-end intelligent electric vehicles, integrating advanced technologies from partnerships with high-tech companies like Huawei [21] Chip Origin (688521) - The company reported significant growth in its chip design and mass production businesses, with a 290.82% quarter-on-quarter increase in design revenue and a 132.77% increase in mass production revenue [22] Tencent Holdings (00700) - Tencent's performance exceeded expectations with a 15.4% year-on-year revenue growth, driven by strong sales and R&D efficiency, leading to a notable increase in net profit [23] China Resources Land (01109) - The company is transitioning its real estate service platform to offer comprehensive lifecycle services, enhancing customer engagement through a new digital platform [24] China Merchants Energy Shipping (601872) - The company is benefiting from rising oil shipping rates, with Q4 2025 VLCC average rates reaching $94,000 per day, marking a significant increase in operational profits [26]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) expects a loss of 11 million to 18 million yuan in 2025, with a non-recurring loss of 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and steadily advanced market development, resulting in revenue growth during the reporting period [1] - Fixed asset scale has expanded due to the completion and delivery of fundraising projects, leading to increased depreciation and amortization expenses [1] Group 2: Investment and Development - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Bio-pharmaceutical Co., Ltd., is still in the innovative drug research and development phase and has not yet generated revenue [1] - The company has conducted impairment tests on inventory and investment properties at the end of the reporting period, recognizing corresponding impairment provisions based on prudence [1]

Core Viewpoint - Chengda Pharmaceutical is forecasting a net loss attributable to shareholders of the listed company for the year 2025, estimated between 11 million to 18 million yuan, with a net loss excluding non-recurring gains and losses projected between 27.5 million to 34.5 million yuan [1] Group 1: Financial Performance - The company has implemented effective sales strategies and market development efforts, leading to a steady increase in operating revenue [1] - The expansion of fixed assets due to completed fundraising projects has resulted in increased depreciation and amortization expenses [1] - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Biomedical Co., Ltd., is still in the research and development phase for innovative drugs and has not yet generated revenue [1] Group 2: Impairment and Non-Recurring Gains - The company conducted impairment tests on inventory and investment properties at the end of the reporting period, leading to the recognition of impairment provisions, which negatively impacted net profit [1] - Non-recurring gains and losses are expected to affect net profit by approximately 16.5 million yuan, primarily from government subsidies and cash management investment income [1] Group 3: Year-on-Year Comparison - Despite the forecasted losses, the company expects a reduction in the loss margin compared to the same period last year [1]

Financial Performance - The company expects a net loss of between RMB 11 million and RMB 18 million for the fiscal year 2025, compared to a loss of RMB 28.1 million in the same period last year[5]. - The net loss after deducting non-recurring gains and losses is projected to be between RMB 27.5 million and RMB 34.5 million, an improvement from a loss of RMB 57.67 million in the previous year[5]. - Basic earnings per share are estimated to be between -0.0726 yuan and -0.1188 yuan, compared to -0.1849 yuan per share last year[5]. - The company is in a loss position but has narrowed the loss margin compared to the same period last year[8]. Revenue and Expenses - The company has implemented effective sales strategies and market development efforts, leading to a steady increase in operating revenue[8]. - The increase in fixed asset scale due to completed investment projects has resulted in higher depreciation and amortization expenses[8]. - Non-recurring gains and losses are expected to impact net profit by approximately RMB 16.5 million, mainly from government subsidies and cash management investment income[8]. Research and Development - The wholly-owned subsidiary, Shanghai Jiuqian Cheng Bio-pharmaceutical Co., Ltd., is still in the R&D phase for innovative drugs and has not yet generated revenue[8]. Financial Reporting and Investor Guidance - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the 2025 annual report[9]. - Investors are advised to make cautious decisions and be aware of investment risks[9].

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, with a closing price of 39.67 yuan and a drop of 4.16%, indicating that the stock is in a state of breaking its initial public offering (IPO) price [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - On its first day of trading, the stock reached a peak price of 188.00 yuan, which remains the highest point since its listing [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including "pharmaceutical intermediates, raw materials, and R&D center expansion" as well as "supplementing working capital" [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [2] Group 3 - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin being a Chinese national who holds permanent residency in Canada [3] - On July 3, 2023, the company announced its 2022 annual equity distribution plan, which involves a cash distribution of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares [3] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [3]

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]